Freedom Biosciences develops next-generation viable and efficacious ketamine and psychedelic therapeutics, with a focus on improving durability and access to treatments for severe mental illness. Its lead program, FREE001, is a ketamine-specific treatment that in a Phase 2 investigational study produced approximately 14 days of antidepressant effects—two to three times longer than typical ketamine alone. The company says the new financing will be used to advance its lead ketamine program and to further multiple additional exploratory programs. Freedom was co-founded in April 2021 by Dr. John Krystal and Dina Burkitbayeva; Burkitbayeva serves as CEO and Krystal as Chief Scientific Advisor. The company emerged from stealth in 2022 and is backed by investors including MBX Capital, PsyMed Ventures and Village Global. Its leadership and advisory board include clinicians and researchers with extensive experience in ketamine and psychedelic research, supporting clinical development and regulatory strategy.

Total raised

$11M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2022